Cytyc, Xoft settles brachytherapy IP row:
This article was originally published in Clinica
Executive Summary
Cytyc, the Marlborough, Massachusetts-based specialist in women's health and cancer diagnostics, has resolved an intellectual property dispute with radiotherapy company Xoft concerning balloon-based brachytherapy technologies developed by both firms to treat breast cancer patients. The settlement will see Fremont, California-based Xoft pay Cytyc royalties of an undisclosed sum, for which the former will gain the freedom to continue selling its Axxent electronic brachytherapy system. The two companies have also agreed to discuss potential opportunities to co-develop technologies in several areas, including women's health.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.